All available clinical data on anakinra in COVID-19: an updated comprehensive review [PDF]
Marzieh Shahrabi +4 more
openalex +1 more source
The use of anakinra in a patient with gout and long-term follow-up of rheumatoid arthritis
, 2023 Е. В. Черемушкина +4 more
openalex +2 more sources
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry [PDF]
, 2022 Gabriella Giancane +23 more
openalex +1 more source
Post-infection immunocomplex glomerulonephritis and Legionnaires' disease in a patient with adult Still's disease during treatment with interleukin 1 receptor antagonist anakinra: a case report [PDF]
, 2011 Dieter Scholtze +2 more
openalex +1 more source
Impact of Anakinra Treatment on Cytokine and Lymphocytes/ Monocytes Profile of an Erdheim-Chester Patient [PDF]
, 2014 Sabina Ševčı́ková +8 more
openalex +1 more source
The off-label use of anakinra in pediatric systemic autoinflammatory diseases [PDF]
, 2020 Valerio Maniscalco +6 more
openalex +1 more source
Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: A case report and review of the literature [PDF]
, 2018 Cinzia Marchica +4 more
openalex +1 more source
Anakinra After Corticosteroid and/or Tocilizumab Treatment in Patients with Severe COVID-19 Pneumonia and Moderate Hyperinflammation. A Retrospective Cohort Study. [PDF]
, 2020 Ismael Francisco Aomar-Millán +10 more
openalex +1 more source
Circulating IL-6 but not neutrophil extracellular traps levels can predict anakinra effectiveness in patients with severe COVID-19 [PDF]
, 2022 Vanessa Granger +9 more
openalex +1 more source
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome [PDF]
, 2003 Hawkins, PN, Lachmann, HJ, McDermott, MF
core +1 more source